EVALUATION OF SPENT PHARMACOTHERAPY IN THE PATIENTS WITH CORONARY HEART DISEASE ASSOCIATED WITH PULMONARY TUBERCULOSIS BY MEANS OF THE NEURAL NETWORK
Abstract and keywords
Abstract (English):
Current, the programs of mass prevention of the cardiovascular diseases, based on preventive medicinal correction of risk factors of cardiovascular diseases, such as hyperlipidemia, arterial hypertension, diabetes mellitus, are developed and realized. Pulmonary tuberculosis influences on state of blood system, which can be considered as functional disorders of the cardiovascular system caused by tuberculosis. These violations caused by concomitant tuberculosis lung diseases, such as cardiovascular and other diseases of the respiratory system. Specific (tuberculosis) damages of the heart and blood vessels are rare and currently their influence on pathomorphosis of tuberculosis isn’t expressed. Modern schemes of treatment of coronary heart disease and hypertension are also applicable to patients with Pulmonary tuberculosis. Effective treatment of coronary heart disease and hypertension in patients with tuberculosis by means of the drugs, allows to normalize the function of the cardiovascular system and to carry out long-chemotherapy by anti-TB drugs and cures of tuberculosis. The study showed the ability to predict the degree of lipid-lowering effect in patients with coronary heart disease in combination with infiltrative tuberculosis of the lungs that can provide the right choice of drug in lipid-lowering therapy.

Keywords:
arterial hypertension, coronary heart disease, lipid-lowering drugs, infiltrative tuberculosis of lung, neural networks.
References

1. Aronov D.M. Statiny – osnovnoe lekarstven-noe sredstvo dlya real´nogo snizheniya smertnosti ot IBS. Russkiy meditsinskiy zhurnal. 2012. №4. S. 1–7.

2. Subklinicheskiy ateroskleroz kak faktor riska serdechno-sosudistykh oslozhneniy / Boytsov S.A., Kukharchuk V.V., Karpov Yu.A. [i dr.]. Kardiovaskulyarnaya terapiya i profilaktika. 2012. №11(3). S. 82–86.

3. Gratsianskiy N.A. Statiny: Sovremennye predstavleniya o gipolipidemicheskoy terapii. Obzor rekomendatsiy EAS/ESC Guidelines for the management of dyslipidemias. M.: 2011.

4. Bulgakova I.V., Bulusheva O.Yu., Shvetsov A.D. Izuchenie svyazi polimorfizma Val432Leu gena CYP 1V1 s razvitiem gipertonicheskoy bolezni v populyatsii russkikh zhiteley Tsentral´noy Rossii. Kurskiy nauchno-prakticheskiy vestnik «Chelovek i ego zdorov´e». 2013. №3. S. 11–16.

5. Rassel S. Iskusstvennyy intellekt: sovremennyy podkhod, 2006. 1424 s.

6. Men´shikov A.A, Belov V.V., Aksenov V.V. 30-i letnyaya vyzhivaemost´ u muzhchin 40-59 let v zavisimosti ot nalichiya arterial´noy gipertenzii i infarkta miokarda. Vestnik YuUrGU. 2012. №42. S. 99–104.

7. Ftiziatriya. Natsional´noe rukovodstvo/pod red. M.I.Perel´mana. M.: GEOTAR-Media, 2007. 512 s.

Login or Create
* Forgot password?